Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Nonhematologic Malignancies 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neurofibrosarcoma 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Meningeal Neoplasms 1Lymphoma 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Doxorubicin 5pazopanib 4Ifosfamide 3pembrolizumab 2Sunitinib 2Radiotherapy, Conformal 2Radiotherapy 2tremelimumab 1temsirolimus 1sintilimab 1saracatinib 1sapanisertib 1romidepsin 1olaratumab 1liposomal doxorubicin 1indolepropanol phosphate 1eribulin 1durvalumab 1Watchful Waiting 1Surgical Procedures, Operative 1Sorafenib 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiation 1Polymerase Chain Reaction 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Methotrexate 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histiocytoma, Malignant Fibrous × sapanisertib × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡